Fig. 4: TTK silencing enhances cisplatin sensitivity in ovarian cancer cells.

A Western blotting was performed to detect the TTK protein level in CAOV3 and OV90 cells treated with different concentrations of cisplatin (0, 0.5, or 1 μg/ml for CAOV3 and 0, 2, or 4 μg/ml for OV90) for 48 h. B−D CAOV3 and OV90 cells stably transfected with PLKO.1 or the TTK shRNA (shTTK1 and shTTK2) were treated with different concentrations of CDDP (0, 0.5, or 1 μg/ml for CAOV3 and 0, 1, or 4 μg/ml for OV90). The MTT assay was performed at 24 h (B) and 48 h (C) and the colony formation assay (D) was performed to evaluate the effect of TTK on CDDP sensitivity. E−G CAOV3 and OV90 cells stably transfected with PLKO.1 or shTTK2 were treated with 2 or 4 μg/ml CDDP for 48 h. E, F Western blot assays were conducted to assess the relative protein levels of cleaved PARP, cleaved caspase-3, and TTK normalized to β-actin. G Flow cytometry was used to detect apoptotic cells (data are mean ± SEM, *P < 0.05, **P < 0.01, n = 3).